Guinea-Bissau vs South Sudan: Share of pregnant women with HIV that receive antiretroviral therapy
Guinea-Bissau
79.0%
in 2024
South Sudan
81.0%
in 2024
Guinea-Bissau rank
43rd
South Sudan rank
40th
Share of pregnant women with HIV that receive antiretroviral therapy over time
- Guinea-Bissau
- South Sudan
How they compare
South Sudan currently reports 81.0% against 79.0% in Guinea-Bissau, a difference of 2.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was South Sudan ahead.
Guinea-Bissau ranks 43rd and South Sudan ranks 40th of 84 countries.
Across the 3 decades both report, Guinea-Bissau averaged higher in 2 and South Sudan in 1.
Head to head by decade
| Decade | Guinea-Bissau | South Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.1% | 0.3% | 2.8% | Guinea-Bissau |
| 2010s | 64.7% | 40.7% | 24.0% | Guinea-Bissau |
| 2020s | 68.6% | 76.6% | 8.0% | South Sudan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of pregnant women with hiv that receive antiretroviral therapy, Guinea-Bissau or South Sudan?
- South Sudan, at 81.0% against 79.0% in Guinea-Bissau as of 2024.
- What is the difference in share of pregnant women with hiv that receive antiretroviral therapy between Guinea-Bissau and South Sudan?
- 2.0%, with South Sudan ahead.
- How many years of comparable data are there for Guinea-Bissau and South Sudan?
- 25 years are reported by both, from 2000 to 2024.
- How do Guinea-Bissau and South Sudan rank globally for share of pregnant women with hiv that receive antiretroviral therapy?
- Guinea-Bissau ranks 43rd and South Sudan ranks 40th of 84 countries.
- Where does this data come from?
- UNAIDS estimates, via World Bank (2026) – processed by Our World in Data, published as Share of pregnant women with HIV that receive antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral medicine is used to prevent mother-to-child transmission of HIV.